Physician profile
Murhaf E Naddour
NPI 1689664559
$503.89
in general payments reported to CMS, 2019-2025
15 companies · $18.35 in 2025
The $18.35 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $287 · 2023: $198 · 2025: $18.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $216.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $81.86 | 2022-2023 | |
| Cumberland Pharmaceuticals, INC. | $63.33 | 2022-2023 | Caldolor |
| Organon LLC | $54.29 | 2022-2023 | Nexplanon |
| Mayne Pharma Commercial LLC | $50.55 | 2022 | |
| Sumitomo Pharma America, INC. | $48.79 | 2023 | Myfembree |
| Myovant Sciences INC. | $32.35 | 2022 | |
| Minerva Surgical, INC | $29.55 | 2022 | |
| Daiichi Sankyo INC. | $26.24 | 2023 | Injectafer |
| Abbvie INC. | $25.91 | 2022 | |
| Haemonetics Corporation | $18.35 | 2025 | Teg6s Hemostasis System |
| Shield Therapeutics INC | $17.46 | 2023 | Accrufer |
| Therapeuticsmd, INC. | $15.79 | 2022 | |
| Hologic Sales and Service, LLC | $13.67 | 2023 | Thinprep 2000 Processor, Aptima |
| Exeltis, USA INC. | $13.45 | 2022 | |
| Baxter Healthcare | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murhaf Naddour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.